- XORTX Therapeutics Inc. (XRTX) has reported positive results from part two of its pharmacokinetics bridging study for the XRX-OXY-101 candidate
- Results showed an increase in the oral effect of the formulation when taken with food
- Also, XORTX confirmed the safety of the drug candidate and no major effects were seen
- The drug candidate is to help treat autosomal dominant polycystic kidney disease
- XORTX Therapeutics Inc. (XRTX) is down 1.00 per cent and is trading at $1.98 per share as of 1:19 p.m. ET
XORTX Therapeutics (XRTX) has reported positive results from part two of its pharmacokinetics bridging study for the XRX-OXY-101 candidate.
The XRX-OXY-101 candidate treats autosomal dominant polycystic kidney disease (ADPKD).
The company stated that the latest results showed a substantial increase in the oral effect of XORTX’s proprietary oxypurinol formulation alongside food compared to fasting. On top of this, phase two also recorded the drug candidate had a clean and safe profile with no adverse or severe side effects.
“Results from arising from this study support the XRx-008 program, understanding of absorption, distribution, metabolism, and excretion (ADME) of oxypurinol in our formulation. These four key ADME criteria influence drug levels, kinetics of drug exposure, performance, and pharmacologic activity of the drug,” Dr. Allen Davidoff, CEO of XORTX, said.
Dr. Davidoff shared that both data sets will guide decision making as the company plans the development of the XRx-008 program clinical and commercial development.
According to XORTX, XRX-OXY-101 was also designed to determine which of the company’s formulations results in the greatest circulating oxypurinol concentrations and oxypurinol exposure and to determine the effect of a range of increasing doses on the bioavailability of the selected formulation.
XORTX Therapeutics Inc. (XRTX) is down 1.00 per cent and is trading at $1.98 per share as of 1:19 p.m. ET.
